<?xml version='1.0' encoding='utf-8'?>
<document id="31335150"><sentence text="Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins."><entity charOffset="19-29" id="DDI-PubMed.31335150.s1.e0" text="Dabigatran" /></sentence><sentence text="Following oral administration, dabigatran etexilate (DABE) is rapidly hydrolyzed to its active form, dabigatran"><entity charOffset="31-51" id="DDI-PubMed.31335150.s2.e0" text="dabigatran etexilate" /><entity charOffset="53-57" id="DDI-PubMed.31335150.s2.e1" text="DABE" /><entity charOffset="101-111" id="DDI-PubMed.31335150.s2.e2" text="dabigatran" /><pair ddi="false" e1="DDI-PubMed.31335150.s2.e0" e2="DDI-PubMed.31335150.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31335150.s2.e0" e2="DDI-PubMed.31335150.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31335150.s2.e0" e2="DDI-PubMed.31335150.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31335150.s2.e1" e2="DDI-PubMed.31335150.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31335150.s2.e1" e2="DDI-PubMed.31335150.s2.e2" /></sentence><sentence text=" DABE, but not dabigatran, presents as a P-glycoprotein (P-gp) substrate and has increasingly been used as a probe drug"><entity charOffset="15-25" id="DDI-PubMed.31335150.s3.e0" text="dabigatran" /><entity charOffset="1-10" id="DDI-PubMed.31335150.s3.e1" text="DABE" /><pair ddi="false" e1="DDI-PubMed.31335150.s3.e1" e2="DDI-PubMed.31335150.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31335150.s3.e1" e2="DDI-PubMed.31335150.s3.e0" /></sentence><sentence text=" Therefore, although dosed as DABE, a P-gp drug-drug interaction (DDI) is reported as a dabigatran plasma concentration ratio (perpetrator versus placebo)"><entity charOffset="88-98" id="DDI-PubMed.31335150.s4.e0" text="dabigatran" /><entity charOffset="30-39" id="DDI-PubMed.31335150.s4.e1" text="DABE" /><pair ddi="false" e1="DDI-PubMed.31335150.s4.e1" e2="DDI-PubMed.31335150.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31335150.s4.e1" e2="DDI-PubMed.31335150.s4.e0" /></sentence><sentence text=" Because the majority of a DABE dose (80 to 85%) is recovered in urine as unchanged dabigatran (renal active secretion is ∼25% of total clearance), dabigatran was evaluated in vitro as a substrate of various human renal transporters"><entity charOffset="84-94" id="DDI-PubMed.31335150.s5.e0" text="dabigatran" /><entity charOffset="148-158" id="DDI-PubMed.31335150.s5.e1" text="dabigatran" /><entity charOffset="27-36" id="DDI-PubMed.31335150.s5.e2" text="DABE" /><pair ddi="false" e1="DDI-PubMed.31335150.s5.e2" e2="DDI-PubMed.31335150.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31335150.s5.e2" e2="DDI-PubMed.31335150.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31335150.s5.e2" e2="DDI-PubMed.31335150.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31335150.s5.e0" e2="DDI-PubMed.31335150.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31335150.s5.e0" e2="DDI-PubMed.31335150.s5.e1" /></sentence><sentence text=" Active (pyrimethamine-sensitive) dabigatran uptake was observed with human embryonic kidney (HEK) 293 cells expressing multidrug and toxin extrusion protein 1 (MATE1) and 2K (MATE2K), with Michaelis-Menten constant (Km) values of 4"><entity charOffset="9-22" id="DDI-PubMed.31335150.s6.e0" text="pyrimethamine" /><entity charOffset="34-44" id="DDI-PubMed.31335150.s6.e1" text="dabigatran" /><pair ddi="false" e1="DDI-PubMed.31335150.s6.e0" e2="DDI-PubMed.31335150.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31335150.s6.e0" e2="DDI-PubMed.31335150.s6.e1" /></sentence><sentence text="0 and 8" /><sentence text="0 μM, respectively" /><sentence text=" By comparison, no uptake of 2 μM dabigatran (versus mock-transfected HEK293 cells) was evident with HEK293 cells transfected with organic cation transporters (OCT1 and OCT2) and organic anion transporters (OAT1, 2, 3, and 4)" /><sentence text=" The efflux ratios of dabigatran across P-gp- and BCRP (breast cancer resistance protein)-MDCK (Madin-Darby canine kidney) cell monolayers were 1"><entity charOffset="22-32" id="DDI-PubMed.31335150.s10.e0" text="dabigatran" /></sentence><sentence text="5 and 2" /><sentence text="0 (versus mock-MDCK cell monolayers), suggesting dabigatran is a relatively poor P-gp and BCRP substrate"><entity charOffset="49-59" id="DDI-PubMed.31335150.s12.e0" text="dabigatran" /></sentence><sentence text=" Three of five drugs (verapamil, ketoconazole, and quinidine) known to interact clinically with dabigatran, as P-gp inhibitors, presented as MATE inhibitors in vitro (IC50 = 1"><entity charOffset="22-31" id="DDI-PubMed.31335150.s13.e0" text="verapamil" /><entity charOffset="33-45" id="DDI-PubMed.31335150.s13.e1" text="ketoconazole" /><entity charOffset="51-60" id="DDI-PubMed.31335150.s13.e2" text="quinidine" /><entity charOffset="96-106" id="DDI-PubMed.31335150.s13.e3" text="dabigatran" /><pair ddi="false" e1="DDI-PubMed.31335150.s13.e0" e2="DDI-PubMed.31335150.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31335150.s13.e0" e2="DDI-PubMed.31335150.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31335150.s13.e0" e2="DDI-PubMed.31335150.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31335150.s13.e0" e2="DDI-PubMed.31335150.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31335150.s13.e1" e2="DDI-PubMed.31335150.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31335150.s13.e1" e2="DDI-PubMed.31335150.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31335150.s13.e1" e2="DDI-PubMed.31335150.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31335150.s13.e2" e2="DDI-PubMed.31335150.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31335150.s13.e2" e2="DDI-PubMed.31335150.s13.e3" /></sentence><sentence text="0 to 25" /><sentence text="2 μM)" /><sentence text=" Taken together, although no basolateral transporter was identified for dabigatran, the results suggest that apical MATE1 and MATE2K could play an important role in its renal clearance"><entity charOffset="72-82" id="DDI-PubMed.31335150.s16.e0" text="dabigatran" /></sentence><sentence text=" MATE-mediated renal secretion of dabigatran needs to be considered when interpreting the results of P-gp DDI studies following DABE administration"><entity charOffset="34-44" id="DDI-PubMed.31335150.s17.e0" text="dabigatran" /><entity charOffset="128-137" id="DDI-PubMed.31335150.s17.e1" text="DABE" /><pair ddi="false" e1="DDI-PubMed.31335150.s17.e0" e2="DDI-PubMed.31335150.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31335150.s17.e0" e2="DDI-PubMed.31335150.s17.e1" /></sentence><sentence text="" /></document>